Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court.
In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other best wide moat stocks to invest in. Russell Investments continues to monitor and ...
Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the positions showed up on publicly available ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results